Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about Phase 2 Trial
Recent news which mentions Phase 2 Trial
< Previous
1
2
3
4
5
6
7
8
9
Next >
Evelo Biosciences Psoriasis Candidate Shows Benefit In Mid-Stage Study
September 27, 2021
Tickers
EVLO
Tags
Psoriasis
News
General
From
Benzinga
Kids Suffer Adverse Reactions In Applied Genetic's Color Blindness Gene Therapy Trial
September 24, 2021
Tickers
AGTC
Tags
Guidance
Earnings
Benzinga
From
Benzinga
Capricor Stock Is Moving Higher As Duchenne Dystrophy Cell Therapy Slows Disease Progression By 71%
September 24, 2021
Tickers
CAPR
Tags
Long Ideas
Duchenne Muscular Dystrophy
News
From
Benzinga
GlycoMimetics' Lead Candidate Data Published In An Online Journal
September 24, 2021
Tickers
GLYC
Tags
Market News
Health Care
Benzinga
From
Benzinga
Vietnam's Health Ministry Approves Phase 2, Phase 3 Cohorts Of Arcturus' COVID-19 Vaccine Trial
September 22, 2021
Tickers
ARCT
Tags
Market News
Health Care
ARCT
From
Benzinga
Why Are Dynavax Technologies Shares Skyrocketing Today?
September 22, 2021
Tickers
DVAX
Tags
Market News
Movers
Health Care
From
Benzinga
Ampio To Test Inhaled COVID-19 Treatment In India
September 21, 2021
Tickers
AMPE
Tags
Biotech
Benzinga
COVID/19 Coronavirus
From
Benzinga
AIM ImmunoTech Receives Positive FDA Response For Ampligen Trial In PCCD Patients
September 21, 2021
Tickers
AIM
Tags
News
General
Penny Stocks
From
Benzinga
Seelos Therapeutics Shares Gain On FDA Approval To Add SLS-005 Regimen In HEALEY ALS Trial
September 21, 2021
Tickers
SEEL
Tags
Movers
Health Care
Market News
From
Benzinga
Aprea Therapeutics Stock Jumps After Eprenetapopt Combo Data Presentation At ESMO
September 21, 2021
Tickers
APRE
Tags
Phase 2 Trial
APRE
Briefs
From
Benzinga
Ocugen's India-Based Partner Concludes COVID-19 Vaccine Trials In Children: Report
September 21, 2021
Tickers
OCGN
Tags
Briefs
OCGN
Phase 2 Trial
From
Benzinga
AstraZeneca's Enhertu Posts Substantial Clinical Benefit Over Roche's Kadcyla In Breast Cancer Trials
September 20, 2021
Tickers
AZN
AZNCF
DSKYF
DSNKY
Tags
General
News
ESMO21
From
Benzinga
Edesa Biotech Stock Is Rallying After COVID-19 Antibody Data: What You Need To Know
September 20, 2021
Tickers
EDSA
Tags
Market News
EDSA
Movers
From
Benzinga
Mirati Unveils Long-term Survival Data For Sitravatinib/Nivolumab Combo In Lung Cancer Patients
September 20, 2021
Tickers
BMY
MRTX
Tags
BMY
ESMO21
News
From
Benzinga
Mirati Posts Adagrasib Data In KRAS-Mutated Lung Cancer, FDA Filing Now On The Cards
September 20, 2021
Tickers
MRTX
Tags
Market News
Health Care
Movers
From
Benzinga
Why Are Synlogic Shares Moving Higher Premarket Monday?
September 20, 2021
Tickers
SYBX
Tags
Biotech
SYBX
why it's moving
From
Benzinga
Pfizer/BioNTech COVID-19 Vaccine Data For Kids Is Here: What You Need To Know
September 20, 2021
Tickers
BNTX
PFE
Tags
Phase 2 Trial
BNTX
Briefs
From
Benzinga
AstraZeneca-Daiichi Sankyo Share Detailed Enhertu Data In Gastric Cancer
September 17, 2021
Tickers
AZN
DSKYF
DSNKY
Tags
General
News
ESMO21
From
Benzinga
Corcept Therapeutics' Relacorilant Combo Therapy Shows Clinical Benefit In Ovarian Cancer
September 17, 2021
Tickers
CORT
Tags
General
News
ESMO21
From
Benzinga
What Is Happening With Innate Pharma Stock On Friday?
September 17, 2021
Tickers
AZN
IPHA
Tags
Phase 2 Trial
Non/Small Cell Lung Cancer
AZN
From
Benzinga
Agenus' Combo Therapy Trial Shows Higher Responses In Cervical Cancer
September 17, 2021
Tickers
AGEN
Tags
Briefs
Trading Ideas
Phase 2 Trial
From
Benzinga
Ayala Pharma Unveils New Interim Data From Rare Cancer Trial With AL101
September 16, 2021
Tickers
AYLA
Tags
Briefs
Trading Ideas
AYLA
From
Benzinga
MacroGenics Shares Fall After MGC018 Data Fails To Impress At ESMO Presentation
September 16, 2021
Tickers
MGNX
Tags
Biotech
why it's moving
Benzinga
From
Benzinga
Biogen Reports Mixed Phase 2 Data For Its Non-Opioid Pain Candidate
September 16, 2021
Tickers
BIIB
Tags
Benzinga
Biotech
Phase 2 Trial
From
Benzinga
Zymeworks' Zanidatamab Aces Mid-Stage Esophageal Cancer Trial
September 16, 2021
Tickers
BGNE
NVS
ZYME
Tags
ESMO21
News
General
From
Benzinga
Leap Therapeutics Stock Is Moving Higher On Updated DKN-01 Combo Trial Data In Gastric Cancer
September 16, 2021
Tickers
BGNE
LPTX
Tags
LPTX
Biotech
Benzinga
From
Benzinga
Aerie Pharma Reports Mixed Bag On Phase 2 Dry Eye Trial
September 16, 2021
Tickers
AERI
Tags
Market News
Health Care
Small Cap
From
Benzinga
Hookipa Pharma, Merck Team Up For Phase 2 Head & Neck Cancer Trial
September 15, 2021
Tickers
HOOK
MRK
Tags
News
General
Long Ideas
From
Benzinga
What's Happening With RedHill Biopharma's Stock On Tuesday?
September 14, 2021
Tickers
RDHL
Tags
News
General
Phase 3 Trial
From
Benzinga
FDA Lifts Clinical Hold On KalVista's Hereditary Angioedema Trial
September 14, 2021
Tickers
KALV
Tags
KALV
Small Cap
hereditary angioedema
From
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.